Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus TRI SPRINTEC.
ENSKYCE vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive